<DOC>
	<DOCNO>NCT00572013</DOCNO>
	<brief_summary>To determine response rate , complete partial , patient indolent lymphoma receive Rituxan BEAM autologous stem cell transplant .</brief_summary>
	<brief_title>Rituxan BEAM With Autologous Peripheral Blood Progenitor Transplant Indolent Lymphoma</brief_title>
	<detailed_description>Objectives : I . To determine response rate , complete partial , patient indolent lymphoma receive Rituxan BEAM autologous stem cell transplant . II . To determine addition Rituxan change toxicity profile attribute high-dose BEAM chemotherapy . This protocol phase I/II trial combine Rituxan pre post-transplant agent aid chemotherapy sensitization treatment minimal residual disease post-transplant .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Any lowgrade Bcell , CD20 positive , nonHodgkin 's lymphoma felt otherwise transplant candidate ( relapse , induction failure , first PR CR ) . Specifically : Small lymphocytic , marginal zone , mantle cell , follicular histology . At least 19 year age Signed write informed consent Expected survival least 6 month Subjects history Tcell lymphoma WHO performance status great equal 2 Subjects without serious disease condition , opinion investigator , would compromise subject 's ability participate study . Nonpregnant nonlactating woman Male female subject reproductive potential able follow accept birth control measure .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>